Dr. Dale Bredesen Announces Termination Of His Relationship With Muses Labs, Inc.

Dec 07, 2015, 14:00 ET from MPI Inc.

NOVATO, Calif., Dec. 7, 2015 /PRNewswire/ -- Dr. Dale Bredesen, Director of the Easton Center for Alzheimer's Research at UCLA, and Founding CEO/Scientist at the Buck Institute for Research on Aging, announced that he has terminated his relationship with Muses Labs, Inc., a Raleigh North Carolina based medical information provider, effective September 10th, 2015. His termination severed all professional and scientific relations with Muses, including consulting, trial participant review, and any interpretation of Muses information.

Dr. Bredesen is an acknowledged leader in the field of Alzheimer's research utilizing combination therapeutics. Dr. Bredesen created MEND Therapy prior to publishing a professional paper detailing the MEND (Metabolic Enhancement of Neurodegeneration) protocol in September of 2014 in the Aging Journal.

The MEND protocol developed by Bredesen has now been utilized by over 100 participants with early Alzheimer's disease or its precursors; MCI or SCI, with a majority showing improvement in symptoms and many able to remain at work or return to work.

Dr. Bredesen and his colleague's company, MPI Inc. will have a website live for interested parties by mid-late January 2016 see http://www.mpitherapeutics.com for more details.

Media Contact:

Todd Brodginski
todd@ReckoningPR.com
323-654-1900

 

SOURCE MPI Inc.



RELATED LINKS

http://www.mpitherapeutics.com